|
1
|
Dent AG, Sutedja TG and Zimmerman PV:
Exhaled breath analysis for lung cancer. J Thorac Dis. 5:S540–S550.
2013.PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
World Health Organization Classification
of Tumors, . Pathology and Genetics of Tumours of the Lung, Pleura,
Thymus and HeartWilliam D, Travis WD, Elisabeth Brambilla E, Konrad
Müller-Hermelink H and Harris CC: IARC Press; Lyon: 2004
|
|
4
|
Wang T, Nelson RA, Bogardus A and Grannis
FW Jr: Five-year lung cancer survival: Which advanced stage
nonsmall cell lung cancer patients attain long-term survival?
Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu MC, Qiu WR, Wang X, Meyer CF and Tan
TH: Human HPK1, a novel human hematopoietic progenitor kinase that
activates the JNK/SAPK kinase cascade. Genes Dev. 10:2251–2264.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Diener K, Wang XS, Chen C, Meyer CF,
Keesler G, Zukowski M, Tan TH and Yao Z: Activation of the c-Jun
N-terminal kinase pathway by a novel protein kinase related to
human germinal center kinase. Proc Natl Acad Sci USA. 94:9687–9692.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chuang HC, Sheu WH, Lin YT, Tsai CY, Yang
CY, Cheng YJ, Huang PY, Li JP, Chiu LL, Wang X, et al: HGK/MAP4K4
deficiency induces TRAF2 stabilization and Th17 differentiation
leading to insulin resistance. Nat Commun. 5:46022014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen YR and Tan TH: Mammalian c-Jun
N-terminal kinase pathway and STE20-related kinases. Gene Ther Mol
Biol. 4:83–98. 1999.
|
|
9
|
Chen YR and Tan TH: The c-Jun N-terminal
kinase pathway and apoptotic signaling (review). Int J Oncol.
16:651–662. 2000.PubMed/NCBI
|
|
10
|
MacCorkle RA and Tan TH: Mitogen-activated
protein kinases in cell-cycle control. Cell Biochem Biophys.
43:451–461. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lam D, Dickens D, Reid EB, Loh SH, Moisoi
N and Martins LM: MAP4K3 modulates cell death via the
post-transcriptional regulation of BH3-only proteins. Proc Natl
Acad Sci USA. 106:11978–11983. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu L, Lu L, Zheng A, Xie J, Xue Q, Wang
F, Wang X, Zhou H, Tong X, Li Y, et al: miR-199a-5p and let-7c
cooperatively inhibit migration and invasion by targeting MAP4K3 in
hepatocellular carcinoma. Oncotarget. 8:13666–13677.
2017.PubMed/NCBI
|
|
13
|
Zhao B, Han H, Chen J, Zhang Z, Li S, Fang
F, Zheng Q, Ma Y, Zhang J, Wu N and Yang Y: MicroRNA let-7c
inhibits migration and invasion of human non-small cell lung cancer
by targeting ITGB3 and MAP4K3. Cancer Lett. 342:43–51. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hsu CP, Chuang HC, Lee MC, Tsou HH, Lee
LW, Li JP and Tan TH: GLK/MAP4K3 overexpression associates with
recurrence risk for non-small cell lung cancer. Oncotarget.
7:41748–41757. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Markou A, Tsaroucha EG, Kaklamanis L,
Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of
mature microRNA-21 and microRNA-205 overexpression in non-small
cell lung cancer by quantitative real-time RT-PCR. Clin Chem.
54:1696–1704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bueno MJ, Pérez de Castro I and Malumbres
M: Control of cell proliferation pathways by microRNAs. Cell Cycle.
7:3143–3148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jovanovic M and Hengartner MO: miRNAs and
apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Bao W, Liu Y, Wang S, Xu S, Li X,
Li Y and Wu S: miR-98-5p contributes to cisplatin resistance in
epithelial ovarian cancer by suppressing miR-152 biogenesis via
targeting Dicer1. Cell Death Dis. 9:4472018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using realtime quantitative PCR and
the 2(Delta Delta C(T)) method. Methods. 25:4024082001. View Article : Google Scholar
|
|
21
|
Chuang JC, Neal JW, Niu XM and Wakelee HA:
Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current
data and future prospects. Lung Cancer. 90:172015. View Article : Google Scholar
|
|
22
|
NSCLC Metaanalyses Collaborative Group, ;
Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le
Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, et al: Adjuvant
chemotherapy, with or without postoperative radiotherapy, in
operable nonsmallcell lung cancer: Two metaanalyses of individual
patient data. Lancet. 375:126712772010.
|
|
23
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dumache R, Rogobete AF, Andreescu N and
Puiu M: Genetic and epigenetic biomarkers of molecular alterations
in oral carcinogenesis. Clin Lab. 61:1373–1381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zahran F, Ghalwash D, Shaker O, Al-Johani
K and Scully C: Salivary microRNAs in oral cancer. Oral Dis.
21:739–747. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soulard A and Hall MN: SnapShot: mTOR
signaling. Cell. 129:4342007. View Article : Google Scholar : PubMed/NCBI
|
